ORLANDO, Florida (Reuters Health) May 21 –
The novel cancer drug STI-571 (Gleevec), a tyrosine kinase inhibitor approved for use in advanced stages of chronic myeloid leukemia (CML), shows dramatic effects in preventing disease progression compared with conventional treatment, new findings show.
In a study of 1106 patients diagnosed with CML, researchers compared the effectiveness of Gleevec to standard drug therapy, interferon plus cytarabine.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!